Orthofix, Inc.

51 articles about Orthofix, Inc.

• Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

  11/18/2022

  Orthofix and SeaSpine announced that John Bostjancic will serve as Chief Financial Officer for the new combined company, effective upon the completion of their pending merger.

• Orthofix and SeaSpine to Combine in Merger of Equals to Create Leading Global Spine and Orthopedics Company

  10/11/2022

  Orthofix and SeaSpine announced they have entered into a definitive agreement to combine in an all-stock merger of equals.

• Orthofix Reports Third Quarter 2021 Results

  11/5/2021

  Orthofix Medical Inc. today reported its financial results for the quarter ended September 30, 2021.

• Orthofix Renews Sponsorship of Olympic Gold Medalist and Spine Patient Laura Wilkinson

  5/19/2021

  Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced its continued sponsorship of Olympic Gold Medalist and Orthofix Spine Patient Laura Wilkinson in her quest for the Tokyo Olympics.

• Orthofix Announces US and European Full Market Launch of OSCAR PRO System for Removal of Cement During Complex Joint Revision Surgeries

  5/17/2021

  Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the U.S. and European full market launch of the OSCAR PRO ™ Ultrasonic Arthroplasty Revision System.

• Orthofix Reports First Quarter 2021 Results

  4/30/2021

  Net sales of $106 million, up 1% compared to prior year, after a strong recovery in March U.S. Spinal Implants net sales grew 19% compared to prior year, as net sales increased for both Spine Fixation and Motion Preservation Performed the first cervical and lumbar procedures utilizing our new 3D-printed titanium interbody implants with Nanovate™ Technology .

• Orthofix Announces Exclusive US License for IGEA’s Bone and Joint Stimulation Devices

  4/28/2021

  Orthofix to pursue FDA approval of IGEA’s solutions to expand the Company’s US Bone Growth Therapy offerings

• Orthofix Announces FDA Clearance and First Patient Implant of the 3D-Printed FORZA Titanium TLIF Spacer System with Nanovate Technology

  4/22/2021

  Designed for TLIF procedures, the 3D-printed FORZA Ti Spacer System further expands the comprehensive line of PEEK, PTC, and now Titanium interbody solutions offered by Orthofix for transforaminal lumbar applications

• Orthofix Announces Board Chair Transition

  4/7/2021

  Ron Matricaria to Conclude Service as Chairman of Orthofix Board of Directors Catherine Burzik to be Nominated for Election at the 2021 Annual Meeting

• Orthofix Announces FDA Clearance and Initial Patient Implant of the Company’s First 3D-Printed Titanium Cervical Spacer System with Nanovate Technology

  4/5/2021

  Designed with nanoscale surface features, the CONSTRUX Mini Ti System is Orthofix’s first 3D-printed titanium (Ti) interbody introduced to the market.

• Orthofix Launches Nationwide Recycling Program to Improve Sustainability

  3/10/2021

  Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced the launch of a nationwide recycling program to improve sustainability efforts.

• Orthofix Reports Fourth Quarter and Fiscal Year 2020 Results

  2/26/2021

  Fourth quarter net sales of $117.6 million, within 3% of our 2019 results US Spine implant sales grew 11% compared to fourth quarter 2019, driven by record M6-C artificial cervical disc performance Strong cash flow performance in the quarter, free cash flow of $17.9 million FITBONE ® intramedullary lengthening and deformity system receives FDA clearance for pediatric indication

• Orthofix Announces Publication of Two-Year Data from the M6-C Artificial Cervical Disc Study

  1/28/2021

  Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced the publication of the full two-year data from its U.S. Investigational Device Exemption (IDE) study of the M6-C ™ artificial cervical disc.

• Orthofix Reports Third Quarter 2020 Results

  11/5/2020

  Net sales of $111.0 million, an increase of 52% sequentially and within 2% of our 2019 performance US Spinal Implants third quarter net sales increased 19% over the prior year Motion Preservation sales in the U.S. of $5.2 million, an increase of 44% sequentially and over 400% over prior year Entered into an investment and co-development partnership with Neo Medical SA

• Paul Gonsalves Joins Orthofix as President of Global Extremities Business

  9/14/2020

  Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced the appointment of Paul Gonsalves as President of the Orthofix Global Extremities business. In this role, Gonsalves will serve on the Company’s Executive Leadership team, reporting to Orthofix President and CEO Jon Serbousek. This press release features multimedia. View the full re

• Orthofix Schedules Second Quarter 2020 Earnings Release and Conference Call for August 6, 2020

  7/27/2020

  Orthofix Medical Inc., a global medical device company focused on musculoskeletal products and therapies, announced that it plans to release financial results for the second quarter 2020 before market open on Thursday, August 6, 2020. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company’s results at 8:30 a.m.

• Orthofix Receives FDA Clearance and CE Mark for the JuniOrtho Plating System

  7/20/2020

  Orthofix Medical Inc., a global medical device company focused on musculoskeletal healing products, announced it has received the U.S. Food and Drug Administration 510 clearance and European CE Mark approval for the JuniOrtho® Plating System.

• Orthofix Announces FDA Clearance and First Patient Implants of FIREBIRD SI Fusion System for Low Back Pain

  6/29/2020

  Orthofix Medical Inc., a global medical device company focused on musculoskeletal healing products, announced the U.S. Food and Drug Administration 510 clearance and the first patient implants of the FIREBIRD™ SI Fusion System.

• Orthofix Reports First Quarter 2020 Results

  5/8/2020

  Net sales of $104.8 million, a decrease of 3.9% compared to prior year and 3.4% on a constant currency basis Cost management initiatives put in place to reduce cash burn Borrowed $100.0 million against the secured revolving credit facility to navigate uncertain macro-environment Closed the acquisition of the FITBONE intramedullary lengthening system assets

• Orthofix Announces Preliminary First Quarter 2020 Results and Provides Business Update

  4/9/2020

  Orthofix Medical Inc. today announced preliminary financial results for the first quarter ended March 31, 2020 and provided a business update.